NYSE:ELN - Elan Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Elan logoElan Corporation Ltd (Elan), formerly Elan Corporation, plc, is a biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. On February 6, 2013, the Company announced that it has entered into an asset purchase agreement with Biogen Idec to transfer to Biogen Idec all Tysabri IP and other assets related to Tysabri. As of 31 December 2012, there were approximately 72,700

Receive ELN News and Ratings via Email

Sign-up to receive the latest news and ratings for ELN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:ELN
CUSIPN/A
Phone+353-1-7094000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

The Truth About Cryptocurrencies

Elan (NYSE:ELN) Frequently Asked Questions

What is Elan's stock symbol?

Elan trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELN."

What is the consensus analysts' recommendation for Elan?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Elan in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Elan been receiving favorable news coverage?

Headlines about ELN stock have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Elan earned a media sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 48.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Elan?

Shares of ELN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Elan?

Elan's mailing address is Treasury Building Grand Canal Street Lower, DUBLIN, 2, Ireland. The biotechnology company can be reached via phone at +353-1-7094000.


MarketBeat Community Rating for Elan (NYSE ELN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  165
MarketBeat's community ratings are surveys of what our community members think about Elan and other stocks. Vote "Outperform" if you believe ELN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.